Takeda Pharmaceutical (NYSE:TAK) Updates FY 2026 Earnings Guidance

Takeda Pharmaceutical (NYSE:TAK) updated its FY 2026 earnings guidance on Thursday. The company provided earnings per share guidance of 3.009-3.009 for the period, compared to the consensus EPS estimate of 1.570. The company issued revenue guidance of $29.6 billion-$29.6 billion, compared to the consensus revenue estimate of $29.0 billion.

Analysts Set New Price Targets

A number of equities analysts have issued reports on TAK shares. Sanford C. Bernstein upgraded Takeda Pharmaceutical from a “market perform” rating to an “outperform” rating in a report on Wednesday, April 8th. Wall Street Zen upgraded shares of Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a report on Saturday, July 18th. Zacks Research downgraded Takeda Pharmaceutical from a “hold” rating to a “strong sell” rating in a research note on Monday, June 29th. Finally, Weiss Ratings downgraded Takeda Pharmaceutical from a “hold (c)” rating to a “hold (c-)” rating in a research note on Tuesday, June 23rd. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold”.

Takeda Pharmaceutical Stock Down 2.8%

Shares of NYSE:TAK traded down $0.49 during midday trading on Thursday, hitting $17.25. 5,613,377 shares of the company’s stock were exchanged, compared to its average volume of 3,133,600. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.09 and a quick ratio of 0.60. The stock has a 50 day moving average price of $16.23 and a 200-day moving average price of $17.07. The company has a market cap of $55.29 billion, a PE ratio of 44.24 and a beta of -0.07. Takeda Pharmaceutical has a 12 month low of $12.99 and a 12 month high of $18.90.

Takeda Pharmaceutical (NYSE:TAK) last announced its quarterly earnings results on Tuesday, March 31st. The company reported $0.56 earnings per share for the quarter. The business had revenue of $6.90 billion for the quarter. Takeda Pharmaceutical had a net margin of 4.31% and a return on equity of 11.20%. On average, sell-side analysts anticipate that Takeda Pharmaceutical will post 1.12 EPS for the current fiscal year.

Hedge Funds Weigh In On Takeda Pharmaceutical

Institutional investors have recently added to or reduced their stakes in the stock. Compound Planning Inc. boosted its stake in Takeda Pharmaceutical by 8.3% in the fourth quarter. Compound Planning Inc. now owns 45,673 shares of the company’s stock valued at $712,000 after acquiring an additional 3,515 shares during the last quarter. Summit Global Investments grew its position in shares of Takeda Pharmaceutical by 22.5% during the 4th quarter. Summit Global Investments now owns 104,373 shares of the company’s stock valued at $1,627,000 after acquiring an additional 19,171 shares during the period. EP Wealth Advisors LLC purchased a new position in Takeda Pharmaceutical in the fourth quarter valued at approximately $360,000. XTX Topco Ltd increased its position in Takeda Pharmaceutical by 437.7% in the fourth quarter. XTX Topco Ltd now owns 71,476 shares of the company’s stock worth $1,114,000 after buying an additional 58,183 shares during the last quarter. Finally, Voloridge Investment Management LLC increased its position in Takeda Pharmaceutical by 1,070.7% in the fourth quarter. Voloridge Investment Management LLC now owns 962,502 shares of the company’s stock worth $15,005,000 after buying an additional 880,289 shares during the last quarter. Institutional investors own 9.17% of the company’s stock.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.